

# Paradeep Phosphates

India | Fertilizers & Agricultural Chemicals | Result Update



5 February 2026

## Current valuation offers huge margin of safety

Paradeep Phosphates (PARADEEP IN) reported slightly weak results as raw materials headwinds weighed on EBITDA growth. Manufactured phosphatic fertilizer volume grew 11% YoY and PARADEEP continues to operate at peak utilization. The company is investing heavily in capacity expansion through debottlenecking as well as Brownfield expansion. A significant part of capex will commercialize in FY29, which enables it to deliver >50% EBITDA growth by FY30 over FY28. Until then, EBITDA may remain flat, as current capacity is fully utilized and benefits from 0.2mn tonne phosphoric acid plant will be offset by erosion of urea business profitability due to expiration of special incentives. However, current valuation at 10.3x TTM EPS of INR 12.8 has already factored in subdued earnings growth and provides huge margin of safety. We retain **Buy** with a higher TP of 247 based on 11.5x H1FY28E EV/EBITDA.

**Capacity expansion underpins the next phase of growth:** PARADEEP outlined a capex of INR 36bn, includes INR 8bn for a 1.0-mn tonne granulation capacity, and INR 15bn toward backward integration, comprising 0.25mn-tonne phosphoric acid and 0.75mn-tonne sulphuric acid capacity at the Odisha site. Around INR 11.5bn is earmarked for phosphoric acid (0.25mn tonne) and sulphuric acid (0.75mn tonne) capacity at the Mangalore plant. Environmental clearance (EC) for the acid plants at PARADEEP is already in place, while EC applications for Mangalore are expected to be filed shortly. For the granulation expansion, the EC process is underway, with public hearings expected shortly and clearance likely by August–September. Management says technical discussions with key equipment suppliers are advancing, with commercial finalization and order placement targeted by March–April. These projects are set to be commissioned by FY29, leading to an incremental EBITDA contribution of INR 14bn (includes debottlenecking initiatives) by FY30 over FY28.

**Debottlenecking initiatives to support margin:** Phosphoric acid capacity of 0.2mn tonne is being added by debottlenecking some processes, with 0.1mn tonnes likely to be commissioned in Q2FY27 and the balance in Q4FY27. In addition, granulation capacity of 0.2mn tonne is being added via debottlenecking by FY28, which should support higher downstream utilization. At Mangalore, a 300-tonne per day sulphuric acid expansion is underway, further strengthening backward integration. These debottlenecking initiatives are likely to support margin and improve operating leverage benefits.

**Retain Buy with a higher TP of INR 247:** The combined entity post the merger benefits from scale, sourcing, distribution reach and a wider product portfolio. After operationalization of new capacity in FY29, PARADEEP will morph into a fertilizer behemoth. The journey from until FY29E may yield limited profit growth but current valuation at 10.3x P/E based on TTM EPS is already factoring it and provides huge margin of safety. We slightly increase our EBITDA estimates by 4% for FY26, by 2% for FY27 and 3% for FY28. We retain **Buy** with a higher TP of 247 from INR 238 based on 11.5x (unchanged) H1FY28E EV/EBITDA. Lower nutrient based subsidy and rising debt are key risks to our call.

### Key financials

YE March (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue (INR mn)	115,751	138,202	217,991	220,454	230,854
YoY (%)	(13.2)	19.4	57.7	1.1	4.7
EBITDA (INR mn)	6,480	12,558	26,279	24,006	27,388
EBITDA margin (%)	5.6	9.1	12.1	10.9	11.9
Adj PAT (INR mn)	999	5,518	14,187	12,668	15,465
YoY (%)	(72.5)	452.3	157.1	(10.7)	22.1
Fully DEPS (INR)	1.2	6.8	13.7	12.2	14.9
RoE (%)	2.8	14.4	25.5	16.0	15.8
RoCE (%)	5.6	12.6	22.3	15.9	16.5
P/E (x)	106.2	19.2	9.5	10.7	8.7
EV/EBITDA (x)	27.5	14.2	6.8	7.4	6.5

Note: Pricing as on 04 February 2026; Source: Company, Elara Securities Estimate

Rating: Buy

Target Price: INR 247

Upside: 90%

CMP: INR 130


As on 04 February 2026

#### Key data

Bloomberg	PARADEEP IN
Reuters Code	PRAO.NS
Shares outstanding (mn)	1,038
Market cap (INR bn/USD mn)	135/1,497
EV (INR bn/USD mn)	178/1,975
ADTV 3M (INR mn/USD mn)	772/9
52 week high/low	234/83
Free float (%)	43

Note: as on 04 February 2026; Source: Bloomberg

#### Price chart



Source: Bloomberg

Shareholding (%)	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26
Promoter	56.1	56.0	57.2	57.7
% Pledge	14.2	14.2	13.9	12.5
FII	7.2	14.0	15.0	11.4
DII	24.5	18.2	14.6	13.3
Others	12.2	11.8	13.2	17.6

Source: BSE

Price performance (%)	3M	6M	12M
Nifty	(0.1)	4.7	10.1
Paradeep Phosphates	(22.3)	(40.2)	10.5
NSE Mid-cap	(1.0)	4.2	11.0
NSE Small-cap	(8.4)	(5.3)	1.8

Source: Bloomberg

#### Prashant Biyani

Fertilizers & Agricultural Chemicals, Hotels, Sugar  
+91 22 6164 8581  
prashant.biyani@elaracapital.com

Associate  
Yashi Jain  
yashi.jain@elaracapital.com



## Financials (YE March)

<b>Income Statement (INR mn)</b>	<b>FY24</b>	<b>FY25</b>	<b>FY26E</b>	<b>FY27E</b>	<b>FY28E</b>
Total Revenue	115,751	138,202	217,991	220,454	230,854
Gross Profit	25,767	35,872	63,337	61,483	66,633
EBITDA	6,480	12,558	26,279	24,006	27,388
EBIT	4,374	10,040	22,440	19,931	23,207
Interest expense	3,660	3,623	4,700	4,281	3,882
Other income	688	1,114	1,225	1,287	1,351
Exceptional/ Extra-ordinary items	-	-	-	-	-
PBT	1,402	7,531	18,966	16,936	20,676
Tax	409	2,006	4,779	4,268	5,210
Minority interest/Associates income	7	(7)	-	-	-
Reported PAT	999	5,518	14,187	12,668	15,465
Adjusted PAT	999	5,518	14,187	12,668	15,465
<b>Balance Sheet (INR mn)</b>	<b>FY24</b>	<b>FY25</b>	<b>FY26E</b>	<b>FY27E</b>	<b>FY28E</b>
Shareholders' Equity	35,644	40,769	70,537	87,639	107,821
Minority Interest	-	-	-	-	-
Trade Payables	14,881	20,283	29,660	30,487	31,494
Provisions & Other Current Liabilities	4,199	4,794	7,908	7,941	8,388
Total Borrowings	39,944	43,408	46,996	45,062	40,867
Other long term liabilities	1,943	2,210	3,344	3,349	3,369
<b>Total liabilities &amp; equity</b>	<b>96,611</b>	<b>111,463</b>	<b>158,444</b>	<b>174,478</b>	<b>191,940</b>
Net Fixed Assets	37,433	38,415	55,560	69,734	82,303
Goodwill	581	581	581	581	581
Intangible assets	18	24	30	30	30
Business Investments / other NC assets	1,010	1,205	1,473	1,422	1,577
Cash, Bank Balances & treasury investments	1,180	11,729	1,642	2,433	2,440
Inventories	18,308	22,870	35,834	36,239	37,949
Sundry Debtors	27,205	25,347	44,793	45,299	47,436
Other Current Assets	10,876	11,293	18,531	18,741	19,624
<b>Total Assets</b>	<b>96,611</b>	<b>111,463</b>	<b>158,444</b>	<b>174,478</b>	<b>191,940</b>
<b>Cash Flow Statement (INR mn)</b>	<b>FY24</b>	<b>FY25</b>	<b>FY26E</b>	<b>FY27E</b>	<b>FY28E</b>
<b>Cashflow from Operations</b>	<b>14,339</b>	<b>13,830</b>	<b>(3,035)</b>	<b>22,932</b>	<b>22,448</b>
Capital expenditure	(4,115)	(3,687)	(2,600)	(18,250)	(16,750)
Acquisitions / divestitures	-	-	-	-	-
Other Business cashflow	447	(2,280)	(1,465)	1,287	1,351
<b>Free Cash Flow</b>	<b>10,670</b>	<b>7,864</b>	<b>(7,100)</b>	<b>5,969</b>	<b>7,049</b>
Cashflow from Financing	(10,589)	2,685	(2,987)	(5,178)	(7,041)
Net Change in Cash / treasury investments	82	10,549	(10,087)	791	8
<b>Key assumptions &amp; Ratios</b>	<b>FY24</b>	<b>FY25</b>	<b>FY26E</b>	<b>FY27E</b>	<b>FY28E</b>
Dividend per share (INR)	0.5	1.0	1.0	1.0	1.0
Book value per share (INR)	43.7	50.0	68.1	84.6	104.0
RoCE (Pre-tax) (%)	5.6	12.6	22.3	15.9	16.5
ROIC (Pre-tax) (%)	5.7	13.7	23.8	16.2	16.8
ROE (%)	2.8	14.4	25.5	16.0	15.8
Asset Turnover (x)	3.2	3.6	4.6	3.5	3.0
Net Debt to Equity (x)	1.1	0.8	0.6	0.5	0.4
Net Debt to EBITDA (x)	6.0	2.5	1.7	1.8	1.4
Interest cover (x) (EBITDA/ int exp)	1.8	3.5	5.6	5.6	7.1
Total Working capital days (WC/rev)	112.8	132.7	129.6	107.0	109.3
<b>Valuation</b>	<b>FY24</b>	<b>FY25</b>	<b>FY26E</b>	<b>FY27E</b>	<b>FY28E</b>
P/E (x)	106.2	19.2	9.5	10.7	8.7
P/Sales (x)	1.2	1.0	0.6	0.6	0.6
EV/ EBITDA (x)	27.5	14.2	6.8	7.4	6.5
EV/ OCF (x)	12.4	12.9	(58.7)	7.8	7.9
FCF Yield	6.0	4.4	(4.0)	3.3	4.0
Price to BV (x)	3.0	2.6	1.9	1.5	1.3
Dividend yield (%)	0.4	0.8	0.8	0.8	0.8

Note: Pricing as on 04 February 2026; Source: Company, Elara Securities Estimate

## Exhibit 1: Quarterly financials

Financials (INR mn)	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)	Q3FY26E	Variance (%)	9MFY26	9MFY25	YoY (%)
<b>Cons Net Sales</b>	<b>57,487</b>	<b>49,896</b>	<b>15.2</b>	<b>68,722</b>	<b>(16.3)</b>	<b>58,728</b>	<b>(2.1)</b>	<b>171,244</b>	<b>119,861</b>	<b>42.9</b>
Raw Materials	44,090	35,279	25.0	52,613	(16.2)	40,255	9.5	127,496	85,219	49.6
% of Net Sales	76.7	70.7	599bp	76.6	14bp	68.5	815bp	74.5	71.1	336bp
Employee Cost	863	779	10.8	819	5.3	1,029	(16.1)	2,485	2,151	15.5
Other Expenses	7,809	8,456	(7.7)	8,724	(10.5)	12,355	(36.8)	24,165	20,569	17.5
Total Expenditure	52,762	44,515	18.5	62,156	(15.1)	53,639	(1.6)	154,146	107,939	42.8
<b>EBITDA</b>	<b>4,725</b>	<b>5,381</b>	<b>(12.2)</b>	<b>6,566</b>	<b>(28.0)</b>	<b>5,089</b>	<b>(7.2)</b>	<b>17,098</b>	<b>11,922</b>	<b>43.4</b>
Margin (%)	8.2	10.8	(257)bp	9.6	(134)bp	8.7	(45)bp	10.0	9.9	4bp
Depreciation	1,018	880	15.7	896	13.6	1,091	(6.7)	2,774	2,352	17.9
<b>EBIT</b>	<b>3,707</b>	<b>4,501</b>	<b>(17.6)</b>	<b>5,671</b>	<b>(34.6)</b>	<b>3,998</b>	<b>(7.3)</b>	<b>14,324</b>	<b>9,570</b>	<b>49.7</b>
Interest	1,270	1,033	23.0	1,403	(9.4)	1,562	(18.7)	3,716	2,991	24.3
Other Income	310	423	(26.8)	417	(25.7)	491	(36.8)	1,067	817	30.6
Exceptional Items	(413)	-	NA	-	NA	-	NA	(413)	-	NA
<b>PBT</b>	<b>3,160</b>	<b>3,891</b>	<b>(18.8)</b>	<b>4,685</b>	<b>(32.6)</b>	<b>2,927</b>	<b>8.0</b>	<b>12,088</b>	<b>7,396</b>	<b>63.4</b>
Tax	513	799	(35.7)	1,266	(59.5)	913	(43.8)	2,850	1,689	68.8
Tax Rate (%)	16.2	20.5	(428)bp	27.0	(1,078)bp	31.2	(1,495)bp	23.6	22.8	75bp
RPAT	2,646	3,093	(14.4)	3,419	(22.6)	2,014	31.4	9,238	5,708	61.9
<b>APAT</b>	<b>2,233</b>	<b>3,093</b>	<b>(27.8)</b>	<b>3,419</b>	<b>(34.7)</b>	<b>2,014</b>	<b>10.9</b>	<b>8,825</b>	<b>5,708</b>	<b>54.6</b>
Adj EPS (INR)	2.7	3.8	(27.8)	4.2	(34.7)	1.9	41.1	10.8	7.0	54.5

Source: Company, Elara Securities Estimate

**Energy efficiency to enhance operating leverage:** PARADEEP continues to focus on energy efficiency improvements in urea, with an investment of INR 2.2bn at the Goa facility. Energy consumption is set to decline from 6.4 Gcal to 6.1 Gcal by Q4FY26, with a payback period of 3–4 years. This initiative is likely to provide operating leverage benefits.

## Exhibit 2: Expansion at Paradeep and Mangalore site to come in by FY29E

Plant	Granulation	Phosphoric & Sulphuric Acid
<b>Location</b>	Paradeep, Odisha	Mangalore, Karnataka
<b>Existing capacity</b>	1.8 MMTPA Granulatin 0.5 MMTPA Phosphoric Acid 1.9 MMTPA Sulphuric Acid	Sulphuric Acid - 0.03 MMTPA existing Sulphuric Acid - 0.10 MMTPA under commissioning
<b>Proposed capacity addition</b>	1.0 MMTPA Granulatin 0.25 MMTPA Phosphoric Acid 0.75 MMTPA Sulphuric Acid	0.25 MMTPA Phosphoric Acid 0.75 MMTPA incremental of Sulphuric Acid
<b>Period for the proposed capacity is to be added</b>	2.5 years	2.5 years
<b>Investment required</b>	INR 24.5bn	INR 11.5bn
<b>Mode of financing</b>	Internal source (30%) and potential external financing options (70%)	

Source: Company, Elara Securities Research

## Exhibit 3: Complex fertilizers sales grows 39% YoY in Q3FY26

(tonne)	Q3FY25	Q3FY26	YoY (%)	Q2FY26	QoQ (%)
<b>Total fertilizer sales volume</b>	<b>870,586</b>	<b>1,069,677</b>	<b>22.9</b>	<b>1,355,103</b>	<b>(21.1)</b>
DAP (Manufactured)	220,178	128,759	(41.5)	127,728	0.8
Complex (Manufactured)	402,954	561,268	39.3	649,575	(13.6)
Urea (Manufactured)	86,588	199,853	130.8	239,809	(16.7)
Traded	160,866	159,471	(0.9)	337,991	(52.8)
SSP	-	20,326	NA	-	NA

Source: Company, Elara Securities Research

## Exhibit 4: Sulphuric acid production up 29% YoY in Q3

Production volume (tonne)	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26
Phosphoric acid	92,360	138,190	125,240	130,370	113,000	120,360	145,000
Sulphuric acid	198,836	363,830	349,650	356,080	283,000	284,219	450,000

Source: Company, Elara Securities Research

## Exhibit 5: Valuation

(INR mn)	H1FY28
EBITDA	25,697
EV/EBITDA (x)	11.5
Target EV	295,517
Net Debt	40,528
Target Market Capitalisation	254,989
Outstanding shares (mn)	1,036
<b>Target Price (INR)</b>	<b>247</b>
CMP (INR)	130
<b>Upside (%)</b>	<b>90</b>
P/E on TP (x)	19.2


Note: pricing as on 4 February 2026; Source: Elara Securities Estimate

## Exhibit 6: Change in estimates

(INR mn)	Earlier			Revised			Change (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Net Sales	219320	224480	230083	217991	220454	230854	(0.6)	(1.8)	0.3
EBITDA	25256	23525	26653	26279	24006	27388	4.1	2.0	2.8
EBITDA margin (%)	11.7	10.5	11.6	12.1	10.9	11.9	35bp	41bp	28bp
PAT	14,754	13180	15822	14187	12668	15465	(3.8)	(3.9)	(2.3)
EPS (INR)	14.2	12.7	15.3	13.7	12.2	14.9	(3.6)	(3.9)	(2.3)
<b>Target price (INR)</b>			<b>238</b>			<b>247</b>			<b>4.0</b>

Source: Elara Securities Estimate

## Coverage History



Date	Rating	Target Price (INR)	Closing Price (INR)
04-Aug-2023	Accumulate	71	65
07-Feb-2024	Accumulate	84	76
16-May-2024	Accumulate	78	70
02-Aug-2024	Buy	112	88
29-Oct-2024	Buy	129	95
05-Feb-2025	Buy	136	111
31-Mar-2025	Buy	147	103
08-May-2025	Accumulate	147	138
30-Jul-2025	Accumulate	238	209
07-Nov-2025	Buy	238	174
04-Feb-2026	Buy	247	130

## Guide to Research Rating

<b>BUY (B)</b>	Absolute Return >+20%
<b>ACCUMULATE (A)</b>	Absolute Return +5% to +20%
<b>REDUCE (R)</b>	Absolute Return -5% to +5%
<b>SELL (S)</b>	Absolute Return < -5%

## Disclosures & Confidentiality for non U.S. Investors

The Note is based on our estimates and is being provided to you (herein referred to as the "Recipient") only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient in understanding / evaluating the Proposal. Nothing in this document should be construed as an advice to buy or sell or solicitation to buy or sell the securities of companies referred to in this document. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. Nevertheless, Elara Securities (India) Private Limited or any of its affiliates is committed to provide independent and transparent recommendation to its client and would be happy to provide any information in response to specific client queries. Elara Securities (India) Private Limited or any of its affiliates have not independently verified all the information given in this Note and expressly disclaim all liability for any errors and/or omissions, representations or warranties, expressed or implied as contained in this Note. The user assumes the entire risk of any use made of this information. Elara Securities (India) Private Limited or any of its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for or solicit investment banking or other business from any company referred to in this Note. Each of these entities functions as a separate, distinct and independent of each other. This Note is strictly confidential and is being furnished to you solely for your information. This Note should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This Note is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Elara Securities (India) Private Limited or any of its affiliates to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe, any such restrictions. Upon request, the Recipient will promptly return all material received from the company and/or the Advisors without retaining any copies thereof. The Information given in this document is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This Information is subject to change without any prior notice. Elara Securities (India) Private Limited or any of its affiliates reserves the right to make modifications and alterations to this statement as may be required from time to time. However, Elara Securities (India) Private Limited is under no obligation to update or keep the information current. Neither Elara Securities (India) Private Limited nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. This Note should not be deemed an indication of the state of affairs of the company nor shall it constitute an indication that there has been no change in the business or state of affairs of the company since the date of publication of this Note. The disclosures of interest statements incorporated in this document are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. Elara Securities (India) Private Limited generally prohibits its analysts, persons reporting to analysts and their family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited. It is important to note that any dispute with respect to this research report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Elara Securities (India) Private Limited was incorporated in July 2007 as a subsidiary of Elara Capital (India) Private Limited.

Elara Securities (India) Private Limited is a SEBI registered Stock Broker in the Capital Market and Futures & Options Segments of National Stock Exchange of India Limited [NSE] and BSE Limited [BSE] and a Depository Participant registered with Central Depository Services (India) Limited [CDSL].

Elara Securities (India) Private Limited's business, amongst other things, is to undertake all associated activities relating to its broking business.

The activities of Elara Securities (India) Private Limited were neither suspended nor has it defaulted with any stock exchange authority with whom it is registered in last five years. However, during the routine course of inspection and based on observations, the exchanges have issued advise letters or levied minor penalties on Elara Securities (India) Private Limited for minor operational deviations in certain cases. Elara Securities (India) Private Limited has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has the certificate of registration been cancelled by SEBI at any point of time.

Elara Securities (India) Private Limited offers research services primarily to institutional investors and their employees, directors, fund managers, advisors who are registered or proposed to be registered.

Details of Associates of Elara Securities (India) Private Limited are available on group company website [www.elaracapital.com](http://www.elaracapital.com)

Elara Securities (India) Private Limited is maintaining arms-length relationship with its associate entities.

Research Analyst or his/her relative(s) may have financial interest in the subject company. Elara Securities (India) Private Limited does not have any financial interest in the subject company, whereas its associate entities may have financial interest. Research Analyst or his/her relative does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Research Analyst or his/her relative or Elara Securities (India) Private Limited or its associate entities does not have any other material conflict of interest at the time of publication of the Research Report.

Artificial Intelligence (AI) tools may have been used only for compilation or collating publicly available research data or internally generated research data during the information gathering and/or summarizing the final report.

Research Analyst or his/her relative(s) has not served as an officer, director or employee of the subject company.

Research analyst or Elara Securities (India) Private Limited have not received any compensation from the subject company in the past twelve months. Associate entities of Elara Securities (India) Private Limited may have received compensation from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities have not managed or co-managed public offering of securities for the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company or third party in connection with the Research Report in the past twelve months.

## Disclaimer & Standard warning

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

## Disclaimer for non U.S. Investors

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

## Disclosures for U.S. Investors

**Rule 15a6 Disclosure:** This research report ("Report") was prepared, approved, published, and distributed by Elara Securities (India) Private Limited a company located outside of the United States (the "Foreign Counterparty"). Avior Capital Markets US LLC ("Avior US"), a US registered broker-dealer, distributes this Report in the US on behalf of the Foreign Counterparty. Only major U.S. institutional investors (as defined in Rule 15a-6 under the US Securities Exchange Act of 1934 (the "Exchange Act")) may receive this Report under the exemption in Rule 15a-6. A US institutional investor must effect any transaction in the securities described in this Report through Avior US.

Neither the Report nor any analyst who prepared or approved the Report is subject to US legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other US regulatory requirements concerning research reports or research analysts. The Foreign Counterparty is not a registered broker-dealer under the Exchange Act nor is it a member of the Financial Industry Regulatory Authority, Inc., or any other US self-regulatory organisation.

**Disclosures on Subject Companies:** Analysts of the Foreign Counterparty produced this material solely for informational purposes and the use of the intended recipient. No person may reproduce, this Report under any circumstances. No person may copy or make this Report available to any other person other than the intended recipient.

Avior US distributes this Report in the United States of America. The Foreign Counterparty distributes this Report elsewhere in the world. This document is not an offer, or invitation by or on behalf of Avior US, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Avior US and the Foreign Counterparty and their affiliates obtained the information contained herein from published information and other sources, which Avior US and the Foreign Counterparty and their affiliates reasonably consider to be reliable.

Avior US and the Foreign Counterparty accept no liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are valid as of the date of this document. Avior US assumes responsibility for the Report content with regards to research distributed in the US.

Neither Avior US nor the Foreign Counterparty has managed or co-managed a public offering of securities for the subject company in the past 12 months, have not received compensation for investment banking services from the subject company in the past 12 months and do not expect to receive and does not intend to seek compensation for investment banking services from the subject company in the next three months. Avior US and the Foreign Counterparty have not owned any class of equity securities of the subject company. There are no other actual, material conflicts of interest of Avior US and the Foreign Counterparty at the time of the publication of this Report. As of the publication of this Report, Avior US nor the Foreign Counterparty makes a market in the subject securities.

Avior US and its affiliates, to the fullest extent permissible by law, accept no liability of any nature whatsoever for any claims, damages or losses arising from, or in connection with, the contents of this Report or the use, reliance, publication, distribution, dissemination, disclosure, alteration or reproduction of this Report, or any views or recommendations recorded therein.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Subject to the applicable laws, all transactions should be executed through Avior US. Aside from within this Report, important conflict disclosures can also be found at <https://aviorcapital.us/us-regulatory-disclosures/and> Investors are strongly encouraged to review this information before investing.

## Additional Disclaimer for UK Investors

Note that Elara Securities (India) Private Limited ("Foreign Counterparty") has concluded a MiFID II research intermediary agreement with Avior Capital Markets International Limited ("Avior UK"), regulated by the Financial Conduct Authority (FRN: 191074), pursuant to which Avior UK distributes the Foreign Counterparty's research in the UK, in return for which the Foreign Counterparty pays Avior UK a percentage of the income received in relation to such research. This research report including any recommendations recorded therein ("Report") have been prepared by the Foreign Counterparty, and not by Avior UK.

The Report: (a) has been objectively prepared from public sources which are believed to be reliable and therefore constitutes independent investment research and is presented as such; and (b) may only be distributed to, and relied on by, qualifying investors, who are permitted to receive same in the UK.

Securities, money market instruments, strategies, financial or investment instruments mentioned in this Report may not be suitable for all investors. The information and opinions provided in this Report do not constitute a personal recommendation/investment advice and take no account of the investor's individual circumstances. Investors should consider this Report as only a single factor in making any investment decisions and, if appropriate, should seek advice from an investment advisor. This Report is not an offer, or invitation by or on behalf of Avior UK, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Save as disclosed otherwise, the Foreign Counterparty's relationship with Avior UK is not reasonably expected to impair the objective presentation of the recommendations in the Report, including any interests or conflicts of interest concerning any financial instruments or the issuers to which the recommendations, directly or indirectly, relate. The Report is deemed to be first disseminated at the date and time recorded on the relevant distribution platform, data network or email (as applicable), and which information is available on request. A list of the Foreign Counterparty's research reports disseminated in the UK over the past 12 months is also available on request.

Avior UK does not assume any responsibility or liability of any nature whatsoever arising from or in connection with the content, use, reliance or dissemination of the Report or any recommendation in respect thereof and disclaims any such liability.

## Certification by Each of the Authors of this Report

The analyst(s) (singular includes plural) ("Analyst") certifies that the views expressed in this Report are an accurate representation of the Analyst's personal opinions on the stock or sector as covered and reported on by the Analyst hereinabove. The Analyst furthermore certifies that no part of the Analyst's compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views as expressed in this document. The Analyst is principally responsible for the preparation of this Report and does not have any material conflict of interest at the time of publication of this Report. The Analyst(s) has not served as an officer, director or employee of the subject company in the last 12-month period ending on the last day of the month immediately preceding the date of publication of the Report.

**Analyst Certification:** In connection with the companies or securities that; each analyst identified in this Report certifies that: The views expressed on the subject companies and securities in this Report reflect their personal views. No part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this Report.

Note that:

- (i) The Foreign Counterparty is the employer of the research analyst(s) responsible for the content of this Report, and
- (ii) Research analysts preparing this Report are resident outside the United States and are not associated persons of any US regulated broker-dealer. Therefore, the analyst(s) are not subject to supervision by a US broker-dealer and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with US rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

**Avior Capital Markets US, LLC** is a FINRA registered broker-dealer (CRD # 172595) formed for that purpose in the State of Delaware with its principal office at 45 Rockefeller Plaza, Suite 2335, New York, New York 10111.

**Avior Capital Markets International Limited** is regulated by the Financial Conduct Authority (FRN: 191074), with its principal office at 10 South Street, Elgin, Scotland IV30 1LE.

**Elara Securities (India) Private Limited** is a SEBI-registered Research Analyst (Regn. No.: INH000000933), Stock Broker (Regn. No.: INZ000238236) and Depository Participant (Regn. No.: IN-DP-370-2018). Its registered address is One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India



## India

**Elara Securities (India) Private Limited**  
One International Center, Tower 3,  
21st Floor, Senapati Bapat Marg,  
Elphinstone Road (West)  
Mumbai – 400 013, India  
Tel : +91 22 6164 8500

## Europe

**Elara Capital Plc.**  
6th Floor, The Grove,  
248A Marylebone Road,  
London, NW1 6JZ,  
United Kingdom  
Tel : +44 20 7486 9733

## USA

**Elara Securities Inc.**  
230 Park Avenue, Suite 2415,  
New York, NY 10169, USA  
Tel: +1 212 430 5870  
Fax: +1 212 208 2501

## Asia / Pacific

**Elara Capital (Asia) Pte.Ltd.**  
One Marina Boulevard,  
Level 20,  
Singapore 018989  
Tel : +65 6978 4047



### Managing Director

**Harendra Kumar** | harendra.kumar@elaracapital.com | +91 22 6164 8571



### Head of Research

**Dr Bino Pathiparampil** | bino.pathiparampil@elaracapital.com | +91 22 6164 8572

## Sales Team



### India

**Hitesh Danak** - hitesh.danak@elaracapital.com - +91 22 6164 8543  
**Ashok Agarwal** - ashok.agarwal@elaracapital.com - +91 22 6164 8558  
**Himani Sanghavi** - himani.sanghavi@elaracapital.com - +91 22 6164 8586



### India, APAC & Australia

**Sudhanshu Rajpal** - sudhanshu.rajpal@elaracapital.com - +91 22 6164 8508  
**Joshua Saldanha** - joshua.saldanha@elaracapital.com - +91 22 6164 8541  
**Shraddha Shrikhande** - shraddha.shrikhande@elaracapital.com - +91 22 6164 8567  
**Suyash Maheshwari** - suyash.maheshwari@elaracapital.com - +91 22 4204 8698



### India & UK

**Prashin Lalvani** - prashin.lalvani@elaracapital.com - +91 22 6164 8544



### India & US

**Karan Rathod** - karan.rathod@elaracapital.com - +91 22 6164 8570



### Corporate Access, Conference & Events

**Anita Nazareth** - anita.nazareth@elaracapital.com - +91 22 6164 8520  
**Tina D'souza** - tina.dsouza@elaracapital.com - +91 22 6164 8595

By clicking this link, you acknowledge and agree to the [Terms and Conditions of Research Services](#).

Access our reports on Bloomberg: Type **RESP ESEC <GO>**

Also available on **Thomson & Reuters**

## Elara Securities (India) Private Limited

Registered Office Address: One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel : +91 22 6164 8500  
CIN: U74992MH2007PTC172297 | SEBI Research Analyst Registration No.: INH000000933  
Member of BSE Limited and National Stock Exchange of India Limited | SEBI REGN. NO.: INZ000238236  
Member of Central Depository Services (India) Limited | SEBI REGN. NO.: IN-DP-370-2018  
Investor Grievance Email ID: investor.grievances@elaracapital.com - Tel. +91 22 6164 8509  
Compliance Officer: Mr. Anand Rao - Email ID: anand.rao@elaracapital.com - Tel. +91 22 6164 8509